THE European Medicines Agency
has recommended changes to the
use of metoclopramide, including
restricting the dosage and duration
of use of the medicine (for short
term use up to five days) to
minimise “known risks of serious
neurological side effects”.
The EMA has also finalised a
review on GLP-1 (gliptin) therapies,
and concluded that presently
available data “do not confirm
recent concerns over an increased
risk of pancreatic adverse events
with these medicines”.The above article was sent to subscribers in Pharmacy Daily's issue from 30 Jul 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Jul 13
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.